A 32-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and weight loss. Chest X-ray shows a cavitary lesion in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is started on standard first-line anti-tuberculous therapy (FLIT). After 2 months of treatment, repeat sputum smear microscopy remains positive. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **treatment failure** — persistent sputum positivity after 2 months of standard first-line therapy. The key differential is between **drug resistance** and **poor adherence**. ## Diagnostic Approach to Treatment Failure **Key Point:** Treatment failure in TB is defined as sputum positivity at ≥5 months of therapy. At 2 months, the first step is NOT to assume drug resistance but to rule out **non-adherence** and confirm susceptibility status. **High-Yield:** The WHO and Indian TB guidelines mandate: 1. **Drug susceptibility testing (DST)** to identify resistance pattern 2. **Adherence assessment** — non-adherence is the most common cause of microbiological failure in resource-limited settings 3. **Continuation of standard therapy** if the isolate is drug-susceptible and adherence is confirmed ## Management Algorithm ```mermaid flowchart TD A[Sputum positive at 2 months of FLIT]:::outcome --> B{Adherence adequate?}:::decision B -->|No| C[Reinforce DOT, counsel patient]:::action B -->|Yes| D[Perform DST]:::action D --> E{Drug-susceptible TB?}:::decision E -->|Yes| F[Continue FLIT with DOT]:::action E -->|No| G[Identify resistance pattern]:::outcome G --> H{MDR-TB?}:::decision H -->|Yes| I[Switch to second-line regimen]:::action H -->|No| J[Tailor regimen based on DST]:::action ``` ## Why This Option is Correct **Clinical Pearl:** In a patient with persistent sputum positivity at 2 months, **adherence failure is more common than drug resistance** in the Indian TB program. DST must be performed urgently, but continuation of standard therapy (with reinforced DOT) is appropriate if the isolate remains susceptible. **Key Point:** Directly observed therapy (DOT) ensures 100% adherence and is the cornerstone of managing suspected non-adherence. ## Differential Management of Other Options | Scenario | Management | |----------|-------------| | Drug-susceptible + poor adherence | Continue FLIT + intensify DOT | | MDR-TB (resistant to INH & RIF) | Second-line regimen (FQ + bedaquiline + linezolid ± others) | | XDR-TB (MDR + resistant to FQ & 2nd-line injectables) | Newer agents (bedaquiline, linezolid, delamanid) | | Monoresistance (e.g., INH-resistant) | Continue RIF-based therapy; extend duration if INH-resistant | [cite:Harrison 21e Ch 205; WHO TB Treatment Guidelines 2023]